Lovastatin induces platelet apoptosis

Area of Science:

• Biochemistry
• Pharmacology
• Hematology

Background:

• Statins are crucial for preventing atherosclerosis and treating coronary artery disease due to their effects on thrombosis.
• The mechanisms behind statin-induced thrombocytopenia and hemorrhage remain unclear.
• Platelet function and apoptosis are critical in thrombotic events.

Purpose of the Study:

• To elucidate the mechanism by which lovastatin affects platelet function and survival.
• To investigate the role of mitochondrial pathways and caspase activation in lovastatin-induced platelet apoptosis.
• To determine if lovastatin impacts platelet activation or aggregation.

Main Methods:

• Assessed mitochondrial inner transmembrane potential and caspase activation in lovastatin-treated platelets.
• Measured P-selectin expression and PAC-1 binding to evaluate platelet activation.
• Quantified collagen- and thrombin-induced platelet aggregation.
• Utilized an integrin αIIbβ3 antagonist (RGDS) to study lovastatin's effects on apoptosis.
• Administered lovastatin to mice to assess in vivo effects on circulating platelet counts.

Main Results:

• Lovastatin dose-dependently induced mitochondrial depolarization, up-regulated Bak, down-regulated Bcl-XL, and activated caspases-3/8/9.
• Lovastatin did not increase platelet surface P-selectin expression or PAC-1 binding.
• Collagen- and thrombin-induced platelet aggregation were significantly reduced by lovastatin.
• RGDS inhibited lovastatin-induced apoptosis in human platelets and integrin αIIbβ3-expressing CHO cells.
• Lovastatin administration reduced circulating platelet counts in mice.

Conclusions:

• Lovastatin induces caspase-dependent apoptosis in platelets via mitochondrial pathway disruption.
• Lovastatin impairs platelet function and reduces circulating platelets in vivo without causing platelet activation.
• These findings suggest a potential mechanism for statin-associated thrombocytopenia and hemorrhage.